-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Assumes Gilead Sciences at Buy, Raises Price Target to $145

Benzinga·01/07/2026 13:52:26
Listen to the news
UBS analyst Michael Yee assumes Gilead Sciences (NASDAQ:GILD) with a Buy rating and raises Price Target to $145.